New anti-amyloid drugs approved to treat Alzheimer’s disease have no clinically meaningful positive effects for patients, a major evidence review has concluded. Drugs like Leqembi (lecanemab) and Kinsula (donanemab) have little to no effect on patients’ cognitive decline and… Read More